Amplitude Surgical (AMPLI) | Financial Analysis & Statements
Amplitude Surgical S.A.S. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
279.7M
Total Liabilities
185.0M
Shareholders Equity
94.7M
Debt to Equity
1.95
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Amplitude Surgical Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 106.0M | 100.2M | 87.6M | 82.7M | 88.3M |
| Cost of Goods Sold | 22.3M | 21.2M | 20.3M | 19.0M | 22.7M |
| Gross Profit | 83.7M | 79.0M | 67.3M | 63.7M | 65.6M |
| Gross Margin % | 78.9% | 78.9% | 76.8% | 77.0% | 74.3% |
| Operating Expenses | |||||
| Research & Development | 1.9M | 1.5M | 1.4M | 1.4M | 958.0K |
| Selling, General & Administrative | 16.6M | 16.0M | 14.5M | 13.4M | 13.3M |
| Other Operating Expenses | 12.3M | 11.1M | 13.5M | 11.0M | 5.4M |
| Total Operating Expenses | 30.8M | 28.7M | 29.4M | 25.8M | 19.6M |
| Operating Income | 12.9M | 10.9M | 1.7M | -1.3M | -1.5M |
| Operating Margin % | 12.2% | 10.8% | 1.9% | -1.6% | -1.7% |
| Non-Operating Items | |||||
| Interest Income | 2.9M | 1.6M | 3.9M | 160.0K | 1.3M |
| Interest Expense | 10.1M | 11.1M | 9.3M | 9.6M | 6.6M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.6M | -6.0M | -1.6M | -11.5M | -11.3M |
| Income Tax | 92.0K | 769.0K | 1.2M | 1.9M | 3.3M |
| Effective Tax Rate % | 5.7% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 1.5M | 38.5M | -4.8M | -14.4M | -14.6M |
| Net Margin % | 1.4% | 38.4% | -5.5% | -17.4% | -16.6% |
| Key Metrics | |||||
| EBITDA | 22.8M | 17.8M | 20.3M | 16.3M | 17.4M |
| EPS (Basic) | €0.03 | €0.82 | €-0.09 | €-0.30 | €-0.30 |
| EPS (Diluted) | €0.03 | €0.82 | €-0.09 | €-0.30 | €-0.30 |
| Basic Shares Outstanding | 48021000 | 48021000 | 48021000 | 47805000 | 47805000 |
| Diluted Shares Outstanding | 48021000 | 48021000 | 48021000 | 47805000 | 47805000 |
Income Statement Trend
Amplitude Surgical Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 29.1M | 37.2M | 21.0M | 30.7M | 36.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 14.8M | 11.1M | 10.6M | 17.0M | 8.2M |
| Inventory | 43.3M | 38.0M | 32.9M | 44.5M | 41.5M |
| Other Current Assets | 476.0K | 881.0K | 909.0K | -1.0K | 275.0K |
| Total Current Assets | 94.7M | 95.5M | 96.7M | 94.4M | 93.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 68.2M | 70.6M | 69.2M | 28.7M | 29.3M |
| Goodwill | 234.9M | 223.1M | 219.4M | 220.6M | 223.7M |
| Intangible Assets | 37.3M | 31.8M | 28.0M | 29.2M | 32.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | -2.0K | -1.0K | -1.0K | - |
| Total Non-Current Assets | 184.6M | 170.6M | 162.8M | 174.6M | 182.1M |
| Total Assets | 279.3M | 266.0M | 259.5M | 269.1M | 275.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.1M | 15.5M | 11.4M | 26.8M | 11.1M |
| Short-term Debt | 17.1M | 11.3M | 11.7M | 9.0M | 20.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 2.0M | 2.4M | 2.2M | 2.6M | 1.8M |
| Total Current Liabilities | 46.9M | 41.3M | 43.8M | 38.4M | 46.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 102.0M | 95.2M | 127.3M | 137.7M | 123.9M |
| Deferred Tax Liabilities | 2.1M | 1.7M | 1.7M | 2.1M | 1.5M |
| Other Non-Current Liabilities | 1.0K | - | 2.0K | 18.8M | 213.0K |
| Total Non-Current Liabilities | 136.5M | 128.9M | 163.1M | 173.8M | 158.1M |
| Total Liabilities | 183.4M | 170.2M | 206.9M | 212.2M | 204.3M |
| Equity | |||||
| Common Stock | 480.0K | 480.0K | 480.0K | 478.0K | 478.0K |
| Retained Earnings | 1.5M | 39.2M | -4.4M | -14.1M | -14.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 95.8M | 95.8M | 52.6M | 56.9M | 70.9M |
| Key Metrics | |||||
| Total Debt | 119.1M | 106.5M | 139.1M | 146.8M | 144.4M |
| Working Capital | 47.7M | 54.1M | 52.8M | 56.0M | 46.8M |
Balance Sheet Composition
Amplitude Surgical Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.5M | 38.5M | -4.8M | -14.7M | -14.6M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | 0 | 139.0K | 185.0K |
| Working Capital Changes | -6.8M | 6.4M | -1.7M | -6.2M | 8.2M |
| Operating Cash Flow | -5.3M | 44.9M | -6.5M | -20.8M | -6.3M |
| Investing Activities | |||||
| Capital Expenditures | -10.4M | -11.2M | -5.2M | -5.1M | -5.1M |
| Acquisitions | - | - | - | - | 67.0K |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -12.1M | 53.7M | -5.7M | -5.1M | -4.9M |
| Financing Activities | |||||
| Share Repurchases | -59.0K | 0 | - | - | -105.0K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 9.4M | 11.9M | 2.0M | 105.7M | 20.0M |
| Debt Repayment | -9.9M | -48.8M | -7.9M | -102.8M | -6.0M |
| Financing Cash Flow | 2.5M | -37.4M | -5.5M | 3.4M | 14.3M |
| Free Cash Flow | -14.9M | -11.3M | -4.2M | -7.1M | 2.6M |
| Net Change in Cash | -14.9M | 61.2M | -17.7M | -22.5M | 3.1M |
Cash Flow Trend
Amplitude Surgical Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Sartorius Stedim | 15.8B | 59.45 | 3.86 | 6.59% | 8.98% | 63.11 |
| Safe Orthopaedics | 148.6K | 0.00 | - | 22,908.13% | 52.57% | -1.40 |
| Crossject S.A | 105.6M | - | - | 212.74% | 0.00% | -4.61 |
| Visiomed Group SA | 52.8M | 59.67 | - | 3.64% | 45.95% | 0.32 |
Financial data is updated regularly. All figures are in the company's reporting currency.